摘要
目的探讨粪便中钙卫蛋白水平改变在炎症性肠病(IBD)活动性评估中的临床意义。方法选择35例患者[溃疡性结肠炎(UC)26例,克罗恩病(CD)9例]和正常对照30例,采用ELISA方法测定粪便中钙卫蛋白水平,10例IBD患者检测治疗前后粪便钙卫蛋白水平改变。结果IBD活动期患者粪便钙卫蛋白水平(432.74±389.58)μg/g显著高于缓解期患者(145.52±27.12)μg/g和正常对照组(50.66±18.13)μg/g,活动期轻、中、重度各组之间差异有统计学意义(P<0.01),IBD治疗前后粪便钙卫蛋白水平改变差异有统计学意义(P<0.01)。结论粪便中钙卫蛋白水平可作为IBD活动性评估和临床治疗有效的判断指标。
Objective To investigate the clinical significance with determining the level of fecal calprotectin in the assessment of inflammatory bowel disease（IBD） activity.Methods ELISA assay was used to measure the level of fecal calprotectin in 35 inflammatory bowel disease patients （26 ulcerative colitis,9 Crohn′s disease） and 30 healthy controls.The level of fecal calprotectin before and after treatment was measured in 10 case of IBD patients.Results The fecal calprotectin level of patients with active IBD was significantly higher（432.74±389.58）μg/g than that of patients with remission IBD （145.52±27.12）μg/g and healthy controls（50.66±18.13）μg/g.The level of fecal calprotectin in mild,moderate and severe degree of active group was significantly higher than that in remission group respectively（P〈0.01）.The level of fecal calprotectin changed significantly before and after treatment（P〈0.01）.Conclusion The level of fecal calprotectin can be used as indicator for predicting the activity and the effectiveness of IBD.
出处
《安徽医科大学学报》
CAS
北大核心
2010年第2期258-260,共3页
Acta Universitatis Medicinalis Anhui
